Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × UNKNOWN × 1-dodecylpyridoxal × Clear all

Phase

Status

Sponsor Class

OTHER 8 INDUSTRY 6 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Platinum-resistant Recurrent Ovarian Cancer 1

Interventions

S 1 (combination) 11 Capecitabine 10 Paclitaxel 9 Oxaliplatin 8 Cisplatin 8 apatinib 7 pyrotinib 6 130-nm albumin-bound paclitaxel 6 sintilimab 5 camrelizumab 5 anlotinib 5 Etoposide 5 Carboplatin 5 nimotuzumab 4 Trastuzumab 4 Radiotherapy, Intensity-Modulated 4 Irinotecan 4 Bevacizumab 4 Albumin-Bound Paclitaxel 4 titanium silicide 3 nedaplatin 3 Vinorelbine 3 Temozolomide 3 Tegafur 3 Taxes 3 Radiosurgery 3 Gemcitabine 3 Fluorouracil 3 Epirubicin 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04348032 2022-03-31

APPROVE

ChineseAMS

Phase 2 Unknown

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡